Neuropace (NPCE) vs SS Innovations International (SSII)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neuropace (NPCE) has outperformed SS Innovations International (SSII) over the past year, losing 44.6% versus a loss of 78.7%. Neuropace is the larger company by market cap ($273.9 million vs $254.9 million), about 1.1 times the size, while SS Innovations International is growing revenue faster (+105.7% vs +25.1%). Neuropace converts more of its revenue into profit, with a net margin of -21.5% versus -28.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NPCE | SSII |
|---|---|---|
| Share price | $7.95 | $1.27 |
| Market cap | $273.89M | $254.86M |
| 1-day change | -2.33% | -0.78% |
| YTD return | -48.51% | -77.64% |
| 1-year return | -44.60% | -78.69% |
| 5-year return | -32.80% | — |
| EPS (TTM) | $-0.56 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $99.99M | $42.48M |
| Revenue growth (YoY) | +25.13% | +105.74% |
| Net income (latest FY) | $-21.46M | $-12.13M |
| Gross margin | 77.23% | 46.00% |
| Operating margin | -16.34% | -19.29% |
| Net margin | -21.47% | -28.55% |
| 52-week high | $19.60 | $6.79 |
| 52-week low | $5.46 | $1.12 |
| Distance from 52-week high | -59.44% | -81.30% |
| Analyst consensus | buy | none |
| Avg. price target upside | +53.71% | +451.18% |
| Average volume | 270.76K | 86.18K |
| Shares outstanding | 34.45M | 200.68M |
| Employees | 216 | 483 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NPCE has outperformed SSII by 34.1 percentage points over the past year.
- Neuropace is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -28.5 cents for SS Innovations International.
- SS Innovations International grew revenue faster in its latest fiscal year (+105.74% vs +25.13%).
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Health Care · Medical/Dental Instruments · 216 employees
About SS Innovations International
SSII stock →SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India, Philippines, Indonesia, South America, Iraq, Cyprus, Oman, United Arab Emirates (UAE), Nepal, and internationally. It offers SSi Mantra, a surgical robotic system; and SSi Mudra, a range of stapling, energy, and core instrumentations for surgical systems.
Health Care · Medical/Dental Instruments · 483 employees
NPCE vs SSII FAQ
Which is bigger, Neuropace or SS Innovations International?
Neuropace (NPCE) is larger, with a market capitalization of $273.89M compared with $254.86M for SS Innovations International (SSII).
Which stock has performed better over the past year, NPCE or SSII?
NPCE returned -44.60% over the past 12 months, compared with -78.69% for SSII (price return, excluding dividends). Past performance does not predict future results.
Are Neuropace and SS Innovations International in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.